Northwest Biotherapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 1997
Net Income	-70.78	-62.6	-136.85	179.13	-538.37	-23.57	Upgrade
Depreciation & Amortization	1.84	1.73	1.5	0.59	0.43	-0.3	Upgrade
Share-Based Compensation	4.64	4.41	12.3	15.5	52.21	1.82	Upgrade
Other Operating Activities	9.5	2.82	70.28	-233.51	453.64	-9.81	Upgrade
Operating Cash Flow	-54.8	-53.64	-52.78	-38.3	-32.09	-31.86	Upgrade
Capital Expenditures	-2.34	-3.44	-2.9	-6.02	-6.61	-0.36	Upgrade
Acquisitions	0	0	0	0	-1.53	0	Upgrade
Investing Cash Flow	-2.34	-3.44	-2.9	-6.02	-8.14	-0.36	Upgrade
Common Stock Issued	17.35	15.05	39.29	4.07	26.81	6.87	Upgrade
Share Repurchases	3.43	0	0	0	0	0	Upgrade
Other Financing Activities	38.34	37.71	2.68	44.06	25.88	3.08	Upgrade
Financing Cash Flow	52.26	52.76	41.97	48.13	52.7	9.95	Upgrade
Net Cash Flow	-3.71	-4.84	-8.2	5.19	9.61	-21.85	Upgrade
Free Cash Flow	-57.15	-57.07	-55.68	-44.31	-38.7	-32.22	Upgrade
Free Cash Flow Margin	-4277.47%	-2954.14%	-3308.20%	-4409.35%	-2997.91%	-1336.89%	Upgrade
Free Cash Flow Per Share	-0.05	-0.05	-0.05	-0.04	-0.05	-0.06	Upgrade

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.